冠心病患者体内血小板α颗粒膜蛋白的测定价值

  • 摘要: 应用单克隆抗体SZ-51,通过放射免疫分析测定了94例冠心病患者血小板α颗粒膜蛋白(GMP-140)的活化分子数。实验结果表明:冠心病组患者血小板GMP-140活化分子数比对照组明显增高(P<0.001),急性心肌梗塞(AMI)患者用尿激酶溶栓治疗后12h的血小板GMP-140活化分子数比治疗前1h明显降低(P<0.001)。冠心病患者自身血小板数与血小板GMP-140分子数无线性相关关系(r=0.039,P>0.50),因此我们认为冠心病患者血小板GMP-140的检测,对冠心病诊断及鉴别诊断,尤其对AMI的病因分析、治疗及预后判断都具有重要价值。

     

    Abstract: RIAOFPLATELETGMP┐140INPATIENTSWITHCORONARYHEARTDISEASEDuTongxinWangZizhengShiHongzhenLuXuelongLiuJiaqin(NanjingMedicalRadioimmunoasayCenter,210006)GongHeheZhangZhengyi(CardiacDepartment,NanjingHospitalNo.1,210006)ABSTRACTWithmonoclonalantibodySZ-51,theactivatedlevelsoftheplateletgranulemembraneprotein(GMP-140)of94caseswithcoronaryheartdisease(CHD)areassayedbyRIA.TheresultsshowthatthelevelsofGMP-140withCHDaremuchhigherthanthoseofthecon-trols(P<0.001),andthelevelsofGMP-140withAMI12hoursafterthetreatmentwithurokinaseforthrombolysisareconsiderablylowerthanthelevelsonehourbeforethetreat-ment.Therefore,theassayofGMP-140withCHDisofgreatclinicalsignificanceindiagnos-inganddiferentiatingCHD,especialy,inanalysingpathogeny,monitoringcurativeefectandpredictingprognosisforAMI.Keywordsplateletgranulemembranecoronaryheartdiseaseradioimmunoassay(RIA)

     

/

返回文章
返回